AKT1 and Cognitive impairment: Critically, pretreatment with the IGF‐1R antagonist JB‐1 (0.8 μM in 0.5 μL) or the AKT inhibitor LY294002 (0.8 μM in 0.5 μL) abolished the therapeutic effects of IGF‐1 in SNI mice (Figure 4D–F), implicating IGF‐1R/AKT signaling in the observed rescue of nociceptive and cognitive deficits.